| Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation BF Gage, AD Waterman, W Shannon, M Boechler, MW Rich, MJ Radford Jama 285 (22), 2864-2870, 2001 | 6318 | 2001 |
| Estimation of the warfarin dose with clinical and pharmacogenetic data International Warfarin Pharmacogenetics Consortium New England Journal of Medicine 360 (8), 753-764, 2009 | 1868 | 2009 |
| Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose MJ Rieder, AP Reiner, BF Gage, DA Nickerson, CS Eby, HL McLeod, ... New England Journal of Medicine 352 (22), 2285-2293, 2005 | 1843 | 2005 |
| Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF) BF Gage, Y Yan, PE Milligan, AD Waterman, R Culverhouse, MW Rich, ... American heart journal 151 (3), 713-719, 2006 | 1358 | 2006 |
| Baseline risk of major bleeding in non–ST-segment–elevation myocardial infarction: the CRUSADE (can rapid risk stratification of unstable angina patients suppress ADverse … S Subherwal, RG Bach, AY Chen, BF Gage, SV Rao, LK Newby, TY Wang, ... Circulation 119 (14), 1873-1882, 2009 | 1357 | 2009 |
| Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin BF Gage, C Eby, JA Johnson, E Deych, MJ Rieder, PM Ridker, ... Clinical Pharmacology & Therapeutics 84 (3), 326-331, 2008 | 1001 | 2008 |
| Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin BF Gage, C Van Walraven, L Pearce, RG Hart, PJ Koudstaal, BSP Boode, ... Circulation 110 (16), 2287-2292, 2004 | 984 | 2004 |
| The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) European heart journal 33 (14), 1750-1757, 2012 | 936 | 2012 |
| A pharmacogenetic versus a clinical algorithm for warfarin dosing SE Kimmel, B French, SE Kasner, JA Johnson, JL Anderson, BF Gage, ... New England Journal of Medicine 369 (24), 2283-2293, 2013 | 877 | 2013 |
| Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial SPS3 Study Group The Lancet 382 (9891), 507-515, 2013 | 822 | 2013 |
| Independent predictors of stroke in patients with atrial fibrillation: a systematic review Stroke Risk in Atrial Fibrillation Working Group Neurology 69 (6), 546-554, 2007 | 789 | 2007 |
| Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors E Birman-Deych, AD Waterman, Y Yan, DS Nilasena, MJ Radford, ... Medical care 43 (5), 480-485, 2005 | 788 | 2005 |
| Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing JA Johnson, L Gong, M Whirl‐Carrillo, BF Gage, SA Scott, CM Stein, ... Clinical Pharmacology & Therapeutics 90 (4), 625-629, 2011 | 781 | 2011 |
| CYP4F2 genetic variant alters required warfarin dose MD Caldwell, T Awad, JA Johnson, BF Gage, M Falkowski, P Gardina, ... Blood, The Journal of the American Society of Hematology 111 (8), 4106-4112, 2008 | 666 | 2008 |
| Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics‐guided warfarin dosing: 2017 update JA Johnson, KE Caudle, L Gong, M Whirl‐Carrillo, CM Stein, SA Scott, ... Clinical Pharmacology & Therapeutics 102 (3), 397-404, 2017 | 665 | 2017 |
| The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life BF Gage, AB Cardinalli, DK Owens Archives of internal medicine 156 (16), 1829-1836, 1996 | 468 | 1996 |
| Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin BF Gage, C Eby, PE Milligan, GA Banet, JR Duncan, HL McLeod Thrombosis and haemostasis 91 (01), 87-94, 2004 | 431 | 2004 |
| Warfarin genotyping reduces hospitalization rates: results from the MM-WES (Medco-Mayo Warfarin Effectiveness Study) RS Epstein, TP Moyer, RE Aubert, DJ O'Kane, F Xia, RR Verbrugge, ... Journal of the American College of Cardiology 55 (25), 2804-2812, 2010 | 430 | 2010 |
| Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation SV Shah, BF Gage Circulation 123 (22), 2562-2570, 2011 | 426 | 2011 |
| Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation BF Gage, M Boechler, AL Doggette, G Fortune, GC Flaker, MW Rich, ... Stroke 31 (4), 822-827, 2000 | 420 | 2000 |
Amy D. WatermanProfessor & Director of Patient Engagement, Houston Methodist Hospital & J.C. Walter TransplantEmail verificata su houstonmethodist.org
